UNITED STATES OF AMERICA BEFORE THE FEDERAL TRADE COMMISSION

In the Matter of)	
Valeant PharmaceuticalsInternational, Inc., a corporation.) FTC File No. 151 FTC File No. 161	
	′)	

AGREEMENT CONTAINING CONSENT ORDER

The Federal Trade Commission), having initiated an investigation of the acquistion by Valeant Pharmaceuticals International, Inc. (hereinafter TT0 -(e CP9(n)-4-f5i)-2(on b)

AGREEMENT CONTAINING CONSENT ORDER

In the Matter of Valeant Pharmaceuticals International, Inc.

FTC File No. 1540236 FTC File No. 1640028

- c. all rights to seek judicial review or otherwisheallenge or contest the validity of the Decision and Order entered pursuant to this Consent Agreement; and
- d. any claim under the Equal Access to Justice Act.
- 5. Not later than thirty (30) days after the date this Consent Agreement is signed by the Proposel Respondent, Proposed Respondent shall submit an initial report, pursuant to Section 2.33 of the Commission's Rules, 16 C.F.R. § 2.33. Proposed Respondent shall also submit subsequent reports every thirty (30) days thereafter until the Decision and Orderbecomes final, at which time the reporting obligations contained in the Decision and Order (other than the requirement to submit an initial report pursuant to this Consent Agreement) shall control. Such reports shall be signed by the Proposed Respondent and shall set forth in detail the manner in which the Proposed Respondent have complied and will comply with the Decision and Order. Such reports will not become part of the public record unless and until the Consent Agreement and Decision and Orderepted by the Commission for public comment.
- 6. In each report described in Paragraph 5, Proposed Respondent shall provide sufficient information and documentation to enable the Commission to determine independently whether the Proposed Respondent is in compliance with this Consent Agreement and the Decision and Order. Each report shall be verified by a notarized signature or sworn statement of an employee of the Proposed Respondent specifically authorized to perform this function, or shall be selferified in the manner set forth in 28 U.S.C. § 1746. Section 2.41(a) of the Commission's Rules of Practice requires that an original and two (2) copies of all compliance reports be filed with the Commission. Proposed Respondent shall file an original report and one (1) copy with the Secretary of the Commission, and shall send at least one (1) copy directly to the Bureau of Competition's Compliance Division.
- 7. This Consent Agreement shall not become part of the public record of the proceeding unless and until it is accepted by the Commission. If this Consent Agreement is accepted

AGREEMENT CONTAINING

AGREEMENT CONTAINING CONSENT ORDER

In the Matter of Valeant Pharmaceuticals International, Inc.

FTC File No. 1540236 FTC File No. 1640028

- 15. Proposed Respondent has read the draft Complaint and the Decision and Order contemplated hereby. Proposed Respondent understands that once the Decision and Order has been issued, it will be required to file one or more compliance reports showing that it has fully complied with the Decision and Order.
- 16. Proposed Respondent agrees to comply with the terms of the proposed Decision and Order from the date it signs this Consent Agreement. Proposed Respondent furthe understands that it may be liable for civil penalties in the amount provided by law for each violation of the Decision and Order after it becomes final and effective.

VALEANT PHARMACEUTICALS INTERNATIONAL, INC.

By	• •
•	Joseph C. Papa
	Chairman and Chief Executive Officer
	Valeant Pharmaceuticalisternational, Inc.
	Date:
	Steven C. Sunshiņ€sq.
	Skadden, Arps, Slate, Meagher & Flom,PLL
	Counsel for Valeant Pharmaceutich ternational, Inc.
	Counsel for valeant Filannaceuticalaemational, inc.
	Date:

AGREEMENT CONTAINING CONSENT ORDER

In the Matter of Valeant Pharmaceuticals International, Inc.

FTC File No. 1540236 FTC File No. 1640028

FEDERAL TRADE COMMIS SION

By:	
,	Danica Noble
	Attorney
	Tina Kondo
	Assistant Director
	Charles Harwood
	Director
	Northwest Regional Office
	Deborah L. Feinstein
	Director
	Bureau of Competition
	FEDERAL TRADE COMMISSION
	I LULINAL INADE WIVINGSION